Rare Partners is a non profit company devoted to the development of new therapies and diagnostics in the field of rare diseases.

Inhaled teicoplanin completed phase 1 clinical trial in cystic fibrosis

News - read more

FDA grants Orphan Drug Designation for the use of teicoplanin in Staphylococcus aureus infections in cf patients.

RP announcement - read more

Wellcome Trust supports the development of sirolimus in beta - thalassemia, a collaborative project between Rare Partners and Ferrara University

News - read more
Syndicate content